A randomized controlled trial of rosuvastatin in the prevention of deep vein thrombosis in total knee arthroplasty

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048407

Enrollment

Unknown

Registered

2021-07-06

Start date

2021-08-01

Completion date

Unknown

Last updated

2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage knee disease

Interventions

Group 1:Fondaparinux sodium

Group 2:Rosuvastatin + fondaparinux sodium

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients who are adults requiring total knee replacement for any reason and who consent to this study.

Exclusion criteria

Exclusion criteria: 1. Patients allergic to rosuvastatin; 2. Currently on anticoagulation therapy or receiving statin therapy or have used statins within 3 months; 3. A history of DVT or PTE; 4. Preoperative liver transaminase (AST or ALT) levels exceeding 3 times the upper limit of normal; 5. Creatine Kinase (CK) levels exceed 3 times the upper limit of normal; 6. Family history of thrombosis, currently receiving hormone replacement therapy.

Design outcomes

Primary

Measure	Time frame
Deep vein thrombosis;Serum thromboelastography;D-dimer;C-reactive protein;Interleukin 1,6;TNF-a;	—

Secondary

Measure	Time frame
Total blood loss;Hidden blood loss;	—

Countries

China

Contacts

Public ContactXiao Cong

The Third Hospital of Mianyang, Sichuan Mental Health Center

syygekxc@126.com+86 13890459183

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026